TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10560170

Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy (NRT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Over-the-counter (OTC) use of nicotine replacement therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medical prescription of nicotine substitutes
Number of subjects: 0
Study: 10182199

Group type: EXPERIMENTAL
Intervention: D.A.R.E. program participants
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (did not receive D.A.R.E. program)
Number of subjects: 38
Study: 2071269

Group type: EXPERIMENTAL
Intervention: Voltaren 'A' (50 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Inflaban 'B' (50 mg)
Number of subjects: 20
Study: 6353620

Group type: EXPERIMENTAL
Intervention: Intravenous domperidone 10 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 31486721

Group type: EXPERIMENTAL
Intervention: Early integrated telehealth palliative care
Number of subjects: 1250

Group type: COMPARATOR
Intervention: In-person palliative care
Number of subjects: 1250
Study: 30419404

Group type: EXPERIMENTAL
Intervention: Total alcoholic drinks consumption
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Higher consumption of total alcoholic drinks
Number of subjects: 74
Study: 28278389

Group type: EXPERIMENTAL
Intervention: Perceived appropriateness of pulmonary nodule evaluation strategies in three clinical vignettes with different malignancy risk.
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Surgical resection as an appropriate option for pulmonary nodule management.
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Engagement in shared decision-making with patients for pulmonary nodule management.
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Willingness to enroll patients in randomized trials comparing nodule management strategies.
Number of subjects: 428
Study: 24866259

Group type: EXPERIMENTAL
Intervention: Integration of health promotion, occupational health and safety, and a system for continuous improvements (Kaizen)
Number of subjects: 0
Study: 23386645

Group type: EXPERIMENTAL
Intervention: 1000 IU vitamin D2 daily for 11 weeks
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 1000 IU vitamin D3 daily for 11 weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 21291957

Group type: EXPERIMENTAL
Intervention: Magnesium valproate (MgV; 20mg/kg/day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 19190178

Group type: EXPERIMENTAL
Intervention: Living Lactobacillus plantarum bacteria
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heat-killed Lactobacillus plantarum bacteria
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study: 17127226

Group type: EXPERIMENTAL
Intervention: Levofloxacin 250 mg oral, once daily (LVFX)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg oral, twice daily (CPFX)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo one tablet oral once daily (P group)
Number of subjects: 82
Study: 15023707

Group type: EXPERIMENTAL
Intervention: Mupirocin 2% nasal ointment (n = 793)
Number of subjects: 1602

Group type: COMPARATOR
Intervention: Placebo ointment (n = 809)
Number of subjects: 1602
Study: 11167439

Group type: EXPERIMENTAL
Intervention: Positive intra-operative suggestions
Number of subjects: 140

Group type: COMPARATOR
Intervention: White noise (control)
Number of subjects: 140
Study: 9764893

Group type: EXPERIMENTAL
Intervention: Artificial Neural Network (ANN)
Number of subjects: 890

Group type: COMPARATOR
Intervention: Stepwise multiple logistic regression
Number of subjects: 890
Study: 8158698

Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy and surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 60
Study: 3336380

Group type: EXPERIMENTAL
Intervention: 4 mg nicotine gum
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: 2 mg nicotine gum
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 173
Study: 29380050

Group type: EXPERIMENTAL
Intervention: Patient-specific drill template (PDT) technique
Number of subjects: 78

Group type: COMPARATOR
Intervention: Conventional arthroscopic technique
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Both PDT and Arthroscopic techniques
Number of subjects: 78
Study: 27163519

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (CE) 0.45 or 0.625 mg/Bazedoxifene (BZA) 20 mg
Number of subjects: 3424

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3424
Study: 25697080

Group type: EXPERIMENTAL
Intervention: Targeted individualized falls prevention program
Number of subjects: 752

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 752
Study: 23324984

Group type: EXPERIMENTAL
Intervention: 15D health-related quality of life instrument
Number of subjects: 3268
Study: 21459785

Group type: EXPERIMENTAL
Intervention: Dialysate calcium concentration of 1.12 mmol/L
Number of subjects: 30

Group type: COMPARATOR
Intervention: Dialysate calcium concentration of 1.37 mmol/L
Number of subjects: 30
Study: 18089701

Group type: EXPERIMENTAL
Intervention: Calcium 1200 mg/d with placebo vitamin D (Ca group)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Calcium 1200 mg/d with 1000 IU/d vitamin D2 (CaD group)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Double placebo (control)
Number of subjects: 120
Study: 16929710

Group type: EXPERIMENTAL
Intervention: EEG reactivity to eye opening
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Right temporal theta frequency
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Left central beta frequency
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Left parietotemporal delta frequency
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Right occipital alpha frequency
Number of subjects: 39
Study: 12906343

Group type: EXPERIMENTAL
Intervention: Selenium therapy (200 microg/day)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 10715288

Group type: EXPERIMENTAL
Intervention: Paclitaxel at 175 mg/m(2) over 3 hours every 3 weeks
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Oxaliplatin at 130 mg/m(2) over 2 hours every 3 weeks
Number of subjects: 86
Study: 8881734

Group type: EXPERIMENTAL
Intervention: Immediate communication of FNAB results
Number of subjects: 102

Group type: COMPARATOR
Intervention: Delayed communication of FNAB results
Number of subjects: 102
Study: 1528969

Group type: EXPERIMENTAL
Intervention: Continuous venotonic treatment for one month
Number of subjects: 2295

Group type: EXPERIMENTAL
Intervention: Intermittent venotonic treatment in parallel with active contraceptive treatment from the 10th to the 28th day
Number of subjects: 2295
Study: 7449633

Group type: EXPERIMENTAL
Intervention: 40 mg isosorbide dinitrate (10 subjects)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 4 mg prazosin (20 subjects)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 50 mg dihydralazine (8 subjects)
Number of subjects: 24
Study: 31446423

Group type: EXPERIMENTAL
Intervention: Facebook ratings
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Facebook comments from unofficial sites
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Facebook comments from official sites
Number of subjects: 0
Study: 31141099

Group type: EXPERIMENTAL
Intervention: Low socioeconomic status (L-SES)
Number of subjects: 9498

Group type: EXPERIMENTAL
Intervention: Traumatic stressful events (TSEs)
Number of subjects: 9498
Study: 27916286

Group type: EXPERIMENTAL
Intervention: Relating Therapy (RT)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 29
Study: 25846253

Group type: EXPERIMENTAL
Intervention: Verbascoside 100mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: COMPARATOR
Intervention: Verbascoside 50mg
Number of subjects: 100
Study: 23567399

Group type: EXPERIMENTAL
Intervention: Peaceful Mind intervention (up to 12 weekly in-home sessions and up to eight brief telephone sessions)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Peaceful Mind intervention
Number of subjects: 32

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 32
Study: 22176903

Group type: EXPERIMENTAL
Intervention: Montelukast sodium (5 mg) for 12 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 60
Study: 19475468

Group type: EXPERIMENTAL
Intervention: Bilateral infraorbital injections with 0.5% bupivacaine (Group IOB)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline (Group NS)
Number of subjects: 40
Study: 17429794

Group type: EXPERIMENTAL
Intervention: Endovascular embolization
Number of subjects: 119

Group type: COMPARATOR
Intervention: Surgical clipping
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Endovascular embolization and Surgical clipping
Number of subjects: 119
Study: 16937749

Group type: EXPERIMENTAL
Intervention: Ketoprofen
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nimesulide
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Rofecoxib
Number of subjects: 40
Study: 14597937

Group type: EXPERIMENTAL
Intervention: Hormone therapy (conjugated estrogens and medroxyprogesterone)
Number of subjects: 0
Study: 10400007

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Ifetroban
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Enalapril + Aspirin
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Enalapril + Ifetroban
Number of subjects: 62

Group type: COMPARATOR
Intervention: Enalapril + Placebo
Number of subjects: 62
Study: 7767151

Group type: EXPERIMENTAL
Intervention: Acyclovir (800 mg by mouth daily)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 2179492

Group type: EXPERIMENTAL
Intervention: External fixator
Number of subjects: 0

Group type: COMPARATOR
Intervention: Plaster cast immobilization
Number of subjects: 0
Study: 7271091

Group type: EXPERIMENTAL
Intervention: Minocycline 100 mg once daily for 7 days
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Minocycline 100 mg once daily for 21 days
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Men with initial Chlamydia trachomatis infection
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Men without C. trachomatis infection
Number of subjects: 289
Study: 31201476

Group type: EXPERIMENTAL
Intervention: Dopamine receptor agonist, pramipexole 0.5 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Dopamine receptor antagonist, amisulpride 400 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 28352928

Group type: EXPERIMENTAL
Intervention: Methotrexate plus micronutrients (Group B)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Methotrexate only (Group A)
Number of subjects: 30
Study: 25245858

Group type: EXPERIMENTAL
Intervention: Fine bore NGT
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Fine bore NGT and Wide bore NGT
Number of subjects: 15

Group type: COMPARATOR
Intervention: No NGT (control)
Number of subjects: 15
Study: 23179103

Group type: EXPERIMENTAL
Intervention: High beta-palmitate (HBP) formula (43% of palmitic acid at sn-2, n = 30)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Regular formula with low-beta palmitate (LBP) (14% of palmitic acid at sn-2, n = 28)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Breast-fed infants (n = 25)
Number of subjects: 83
Study: 21915551

Group type: EXPERIMENTAL
Intervention: Total hip arthroplasty in patients with hepatitis C
Number of subjects: 71

Group type: COMPARATOR
Intervention: Total hip arthroplasty in control group
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty in patients with hepatitis C
Number of subjects: 71

Group type: COMPARATOR
Intervention: Total knee arthroplasty in control group
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Combined hepatitis-C group
Number of subjects: 71
Study: 18443258

Group type: EXPERIMENTAL
Intervention: ACEIs or angiotensin receptor blockers
Number of subjects: 1094

Group type: EXPERIMENTAL
Intervention: ACEIs to a BP lower than 130/80 mm Hg
Number of subjects: 1094
Study: 16555143

Group type: EXPERIMENTAL
Intervention: Early Risers 'Skills for Success' conduct problems prevention program
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-intervention comparison group
Number of subjects: 0
Study: 14666764

Group type: EXPERIMENTAL
Intervention: Xiehuo Yangyin powder (XHYY) plus methimazole
Number of subjects: 60

Group type: COMPARATOR
Intervention: Methimazole alone
Number of subjects: 60
Study: 10973545

Group type: EXPERIMENTAL
Intervention: Tepid cardiopulmonary bypass (34 degrees C)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Hypothermic cardiopulmonary bypass (28 degrees C)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 31
Study: 8844718

Group type: EXPERIMENTAL
Intervention: Fructo-oligosaccharides (FOS) 12.5 g/day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (saccharose)
Number of subjects: 20
Study: 1739571

Group type: EXPERIMENTAL
Intervention: Bupivacaine 2 mg kg‐1 with adrenaline 1 in 200,000 plus hyaluronidase 3000 iu
Number of subjects: 22

Group type: COMPARATOR
Intervention: Bupivacaine 2 mg kg‐1 with adrenaline 1 in 200,000 without hyaluronidase
Number of subjects: 22
Study: 6371788

Group type: EXPERIMENTAL
Intervention: Zaditen syrup
Number of subjects: 60

Group type: COMPARATOR
Intervention: Clemastine
Number of subjects: 60
Study: 31764361

Group type: EXPERIMENTAL
Intervention: AquaVac system (low-cost NPWT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: VAC ATS system (commercial NPWT)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both systems
Number of subjects: 36
Study: 29908031

Group type: EXPERIMENTAL
Intervention: Curcumin
Number of subjects: 90

Group type: COMPARATOR
Intervention: Mefenamic acid (Control)
Number of subjects: 90
Study: 26630423

Group type: EXPERIMENTAL
Intervention: Stratified group intervention (STarT Back)
Number of subjects: 583

Group type: EXPERIMENTAL
Intervention: High-risk stratified group
Number of subjects: 583

Group type: EXPERIMENTAL
Intervention: Medium-risk stratified intervention
Number of subjects: 583

Group type: EXPERIMENTAL
Intervention: Low-risk stratified patients
Number of subjects: 583

Group type: COMPARATOR
Intervention: Historical control (generic group intervention)
Number of subjects: 583
Study: 24561494

Group type: EXPERIMENTAL
Intervention: 40 mg daily pravastatin
Number of subjects: 9014

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9014
Study: 22322521

Group type: EXPERIMENTAL
Intervention: Articaine (40 mg with Epinephrine 0.5 mg %)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Articaine (40 mg with Epinephrine 1 mg %)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Mepivacaine (30 mg with Epinephrine 1 mg %)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Mepivacaine (20 mg with Epinephrine 1 mg %)
Number of subjects: 10
Study: 20850004

Group type: EXPERIMENTAL
Intervention: Intravenous artesunate 2·4 mg/kg at 0, 12, and 24 hours, then daily
Number of subjects: 66

Group type: COMPARATOR
Intervention: Intravenous quinine 20mg/kg initially then 10mg/kg three times a day
Number of subjects: 66
Study: 17550648

Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC) alone (6 mg/kg)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC) combined with Albendazole (ALB) (400 mg)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (DEC alone)
Number of subjects: 82
Study: 15370010

Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg daily, with daily dispensing for the first 7 days and weekly dispensing for the following 11 weeks
Number of subjects: 97
Study: 11372045

Group type: EXPERIMENTAL
Intervention: PGV (cisplatin 50 mg/m², gemcitabine 1000 mg/m², vinorelbine 25 mg/m²)
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: PGT (cisplatin 50 mg/m², gemcitabine 1000 mg/m², paclitaxel 125 mg/m²)
Number of subjects: 343

Group type: COMPARATOR
Intervention: PG (cisplatin 100 mg/m², gemcitabine 1000 mg/m²)
Number of subjects: 343
Study: 9215189

Group type: EXPERIMENTAL
Intervention: 5 mg vaginal prostaglandin E2 gel
Number of subjects: 83

Group type: COMPARATOR
Intervention: 0.5 mg intracervical prostaglandin E2 gel
Number of subjects: 83
Study: 8433883

Group type: EXPERIMENTAL
Intervention: MCT formula (38% medium-chain fatty acids)
Number of subjects: 18

Group type: COMPARATOR
Intervention: LCT formula (6% medium-chain fatty acids)
Number of subjects: 18
Study: 3659138

Group type: EXPERIMENTAL
Intervention: Knee extensor muscle torque tracings
Number of subjects: 30
Study: 29693214

Group type: EXPERIMENTAL
Intervention: Transcutaneous vagus nerve stimulation (tVNS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral sham stimulation
Number of subjects: 0
Study: 25405463

Group type: EXPERIMENTAL
Intervention: Airtraq laryngoscope
Number of subjects: 30

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 30
Study: 25500488

Group type: EXPERIMENTAL
Intervention: Liposomal curcumin (10 - 400 mg/m2)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Liposomal curcumin (≥ 120 mg/m2)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Liposomal curcumin (up to 120 mg/m2)
Number of subjects: 50
Study: 23810616

Group type: EXPERIMENTAL
Intervention: Free fibula flap
Number of subjects: 34

Group type: COMPARATOR
Intervention: Deep circumflex iliac artery (DCIA) flap
Number of subjects: 34
Study: 20965846

Group type: EXPERIMENTAL
Intervention: PDLLA screws
Number of subjects: 58

Group type: COMPARATOR
Intervention: Titanium metallic screws
Number of subjects: 58
Study: 18514162

Group type: EXPERIMENTAL
Intervention: NaF
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: H(2)SiF(6)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Natural fluoride
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.67 mg/L solution
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 5.45 mg/L solution
Number of subjects: 10
Study: 16817039

Group type: EXPERIMENTAL
Intervention: Cyclic etidronate therapy (oral regimen repeated every 14 weeks)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Comparison between etidronate and placebo groups
Number of subjects: 31
Study: 12798892

Group type: EXPERIMENTAL
Intervention: TENS device applied on the patient's abdomen before and during office hysteroscopy (group A, n = 71)
Number of subjects: 142

Group type: COMPARATOR
Intervention: No TENS device used (control group B, n = 71)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 142
Study: 10618952

Group type: EXPERIMENTAL
Intervention: Saline dilution (20% with 0.9% saline, 1 ml)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no dilution)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Aspirin (375 mg daily for 3 days)
Number of subjects: 20
Study: 7488989

Group type: EXPERIMENTAL
Intervention: Soft-splint
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Palliative-treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: No-treatment
Number of subjects: 30
Study: 1903558

Group type: EXPERIMENTAL
Intervention: misoprostol, 400 micrograms twice daily
Number of subjects: 15

Group type: COMPARATOR
Intervention: high‐dose liquid antacid regimen
Number of subjects: 15
Study: 7079249

Group type: EXPERIMENTAL
Intervention: Graduated filters
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo filters
Number of subjects: 0

Group type: COMPARATOR
Intervention: Quit smoking on own
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-term quitters
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuing smokers
Number of subjects: 0
Study: 30131043

Group type: COMPARATOR
Intervention: Dual-chamber pacing (DDDR)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Algorithms of minimization of right ventricular pacing (MRVP)
Number of subjects: 74
Study: 27722224

Group type: EXPERIMENTAL
Intervention: Immediate post-extractive ultra-wide 7 mm-diameter implants (group A)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Delayed implant installation 4 months after tooth extraction and socket preservation (group B)
Number of subjects: 24
Study: 24767716

Group type: EXPERIMENTAL
Intervention: Individuals who reported at least one burn injury (3.98% of the population, 145 out of 3645 individuals)
Number of subjects: 3645

Group type: EXPERIMENTAL
Intervention: Individuals with burns seeking care from a traditional healer (21%, 30 out of 145 individuals)
Number of subjects: 3645
Study: 23095376

Group type: EXPERIMENTAL
Intervention: Acupuncture plus usual care
Number of subjects: 233

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 233
Study: 20336635

Group type: EXPERIMENTAL
Intervention: Estrogen‐plus‐progestin therapy (CHT)
Number of subjects: 2502

Group type: EXPERIMENTAL
Intervention: Estrogen therapy (ET)
Number of subjects: 2502

Group type: EXPERIMENTAL
Intervention: Any use of CHT
Number of subjects: 2502

Group type: EXPERIMENTAL
Intervention: Any use of ET
Number of subjects: 2502

Group type: COMPARATOR
Intervention: Control group (non-users of HT)
Number of subjects: 2502

Group type: EXPERIMENTAL
Intervention: Case group (HT users)
Number of subjects: 2502
Study: 18550943

Group type: EXPERIMENTAL
Intervention: Depth jump training
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: VertiMax training
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31
Study: 16028129

Group type: EXPERIMENTAL
Intervention: Therapeutic vaccines (ALVAC-HIV [vCP1452] or ALVAC-HIV and Remune)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 11796648

Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ranitidine (75 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Famotidine (10 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24